Therapeutic Advances in Respiratory Disease · 2022 · 17 citations · 25 references
MedicineClinical SciencesInternal MedicineClinical EpidemiologyPulmonary Function TestingPulmonologyFibrosisInterstitial Lung DiseasePulmonary PathologyRespiratory DiseaseFibrotic Interstitial Lung DiseaseInterstitital Lung DiseaseLung Biopsy DiagnosisLung Disease ProgressionNonspecific Interstitial PneumoniaPrognostic Factors AnalysisProgressive Pulmonary FibrosisSurvival Rates
Aim: Several studies have reported favorable outcomes of nonspecific interstitial pneumonia (NSIP); however, its prognosis and prognostic factors remain unclear. This study aimed to determine the outcomes of fibrotic NSIP and the prognostic factors for progression, relapse, and survival. Methods: In this retrospective study, we reviewed the clinical data of 204 patients diagnosed with fibrotic NSIP by surgical lung biopsy at Samsung Medical Center. The factors associated with survival and disease progression or relapse were determined using Cox proportional hazard analysis. Results: The median age of patients was 54 years and 67 (33%) patients were male. Also, 47 patients (23%) were current or ex-smokers. In all, 141 (69%) patients were diagnosed with idiopathic NSIP, while 63 (31%) patients were associated with connective tissue diseases. Progression or relapse was observed in 100 (49%) patients. The 5-year and 10-year survival rates were 94.6% and 90.4%, respectively. The factors associated with disease progression and relapse were diffusing capacity for carbon monoxide (DLco) <60% [adjusted hazard ratio (HR), 1.739; 95% confidence interval (CI), 1.036–2.921; p = 0.036], bronchoalveolar lavage (BAL) lymphocyte >15% (adjusted HR, 0.592; 95% CI, 0.352–0.994; p = 0.047), and treatment with corticosteroid and azathioprine (adjusted HR, 0.556; 95% CI, 0.311–0.955; p = 0.048). Disease progression or relapse was associated with mortality (adjusted HR, 7.135; 95% CI, 1.499–33.971; p = 0.014). Conclusion: Preserved lung function, BAL lymphocytosis, and treatment with corticosteroids and azathioprine were associated with lower risks of disease progression and relapse, which were risk factors for mortality.
25
Daniel Aletaha, Tuhina Neogi, Alan J. Silman et al. · Arthritis & Rheumatism · 2010 · 9.6K citations · Full text
Medicine, Internal Medicine, Clinical Classification Systems +13
William D. Travis, Ulrich Costabel, David M. Hansell et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 4.3K citations · Full text
F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen et al. · Annals of the Rheumatic Diseases · 2013 · 2.9K citations
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text